Published in Pharma Law Weekly, July 25th, 2006
With submission of this IND, Valera is preparing for a phase 1/2 open label study of its naltrexone implant in healthy volunteers with a history of opioid abuse. A primary objective of this study is to investigate the extent of opiate blockade following morphine challenges.
The lead investigator of the study is addiction researcher and authority on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly